Key Highlights: Implications: Pivot Path’s majority sale to an Ascent-led consortium effectively spins it out as an independent, PE-backed specialist, which should accelerate its growth in...
Key Highlights: Implications: The FTC is allowing Aurobindo’s $250 million Lannett deal only with a divestiture remedy, which should keep competition intact in four generic drug ...
Key Highlights: Implications: This approval moves Enhertu + Perjeta into the front line of HER2‑positive metastatic breast cancer care in India, displacing taxane + tra...
Key Highlights: Implications: The all-cash ₹188 crore acquisition gives Alivira immediate access to BioForLife’s established Italian pet-care business in nutraceuticals...
Key Highlights: Implications: Zaynich’s approval gives Wockhardt a home-grown differentiated anti‑infective positioned squarely at India’s metallo‑β‑lactamase (MBL) and XDR Gram‑...
Key Highlights: Implications: This is a strategic diversification move: Anupam Rasayan is using Bliss GVS to enter pharmaceutical formulations and move further up the healthcare value chai...
Key Highlights: Implications: This means Skymap Pharma is set to take over IMPCL as the government exits ownership, turning a long-running public-sector Ayurvedic and Unani manuf...
Key Highlights: Implications: Align’s new Hyderabad plant is a big capacity and margin move, not just a footprint expansion. It should make the company more resilient on supply, ...
Key Highlights: Implications: GTBL’s MicroBiopharm acquisition is a strategic move to become a more integrated, higher-value pharma services and ingredients player. The mai...
Key Highlights: Implications: The merger gives HAB Pharma a bigger scale story: a cleaner corporate structure, more manufacturing capacity, and a stronger platform to sell specialty products in more ...
